- Home
- INDI vs TSHA Comparison
INDI vs TSHA Comparison
Compare INDI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDI
- TSHA
- Stock Information
- Founded
- INDI 2007
- TSHA 2019
- Country
- INDI United States
- TSHA United States
- Employees
- INDI N/A
- TSHA N/A
- Industry
- INDI Semiconductors
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- INDI Technology
- TSHA Health Care
- Exchange
- INDI Nasdaq
- TSHA Nasdaq
- Market Cap
- INDI 790.2M
- TSHA 728.4M
- IPO Year
- INDI N/A
- TSHA 2020
- Fundamental
- Price
- INDI $3.88
- TSHA $3.07
- Analyst Decision
- INDI Strong Buy
- TSHA Strong Buy
- Analyst Count
- INDI 5
- TSHA 7
- Target Price
- INDI $5.90
- TSHA $8.71
- AVG Volume (30 Days)
- INDI 3.1M
- TSHA 3.5M
- Earning Date
- INDI 11-06-2025
- TSHA 11-12-2025
- Dividend Yield
- INDI N/A
- TSHA N/A
- EPS Growth
- INDI N/A
- TSHA N/A
- EPS
- INDI N/A
- TSHA N/A
- Revenue
- INDI $217,685,000.00
- TSHA $8,098,000.00
- Revenue This Year
- INDI $4.53
- TSHA N/A
- Revenue Next Year
- INDI $31.60
- TSHA N/A
- P/E Ratio
- INDI N/A
- TSHA N/A
- Revenue Growth
- INDI N/A
- TSHA N/A
- 52 Week Low
- INDI $1.53
- TSHA $1.05
- 52 Week High
- INDI $5.57
- TSHA $3.40
- Technical
- Relative Strength Index (RSI)
- INDI 38.31
- TSHA 53.47
- Support Level
- INDI $4.24
- TSHA $3.16
- Resistance Level
- INDI $4.42
- TSHA $2.99
- Average True Range (ATR)
- INDI 0.19
- TSHA 0.17
- MACD
- INDI -0.09
- TSHA 0.01
- Stochastic Oscillator
- INDI 6.93
- TSHA 46.34
About INDI indie Semiconductor Inc.
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.